SCHEMBL11250

SCHEMBL11250

CCC(=O)N(CC)c1ccccc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
HSD17B10 Q99714 2/20 0.51
ESR1 P03372 1/20 0.48
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
KDM4E B2RXH2 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
MCL1 Q07820 1/20 0.43
POLB P06746 1/20 0.43
FPR1 P21462 1/20 0.42
TSPO P30536 2/20 0.42
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30994793 0.85 ESR1 (0.49) ALDH1A1ESR1KMT2AMEN1KDM4E
SCHEMBL10941845 0.85 ESR1 (0.49) ALDH1A1ESR1KMT2AMEN1KDM4E
SCHEMBL11722894 0.83 MEN1 (0.48) ALDH1A1HSD17B10ESR1KMT2AMEN1
SCHEMBL4286533 0.83 ESR1 (0.48) ALDH1A1HSD17B10ESR1KMT2AMEN1
SCHEMBL3207994 0.83 LMNA (0.48) ALDH1A1HSD17B10ESR1KMT2AKDM4E
SCHEMBL11267655 0.83 ALDH1A1 (0.47) ALDH1A1HSD17B10ESR1KDM4ECYP1A2
SCHEMBL30994819 0.83 SMN1; SMN2 (0.47) ALDH1A1HSD17B10ESR1KMT2AMEN1
SCHEMBL12691938 0.83 TSPO (0.55) MAPTTSPO
SCHEMBL6529361 0.81 ESR1 (0.46) ALDH1A1HSD17B10ESR1KMT2AMEN1
SCHEMBL11258983 0.81 ALDH1A1 (0.45) ALDH1A1HSD17B10ESR1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP ALDH1A1 1846/4885HSD17B10 963/4885ESR1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.